[HTML][HTML] Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
C Vogelmeier, D Ramos-Barbon, D Jack, S Piggott… - Respiratory …, 2010 - Springer
Background Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β 2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
[PDF][PDF] Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
C Vogelmeier, D Ramos-Barbon, D Jack, S Piggott… - 2010 - cyberleninka.org
Background: Indacaterol is a novel, inhaled, once-daily, ultra-long-acting b2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
C Vogelmeier, D Ramos-Barbon, D Jack, S Piggott… - Respiratory …, 2010 - infona.pl
Background Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.
C Vogelmeier, D Ramos-Barbon, D Jack… - Respiratory …, 2010 - search.ebscohost.com
Abstract < bold> Background: </bold> Indacaterol is a novel, inhaled, once-daily,
ultra-long-acting β2-agonist for the treatment of chronic obstructive pulmonary disease …
ultra-long-acting β2-agonist for the treatment of chronic obstructive pulmonary disease …
[PDF][PDF] Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
C Vogelmeier, D Ramos-Barbon, D Jack, S Piggott… - 2010 - researchgate.net
Background: Indacaterol is a novel, inhaled, once-daily, ultra-long-acting b2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
[HTML][HTML] Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
C Vogelmeier, D Ramos-Barbon, D Jack… - Respiratory …, 2010 - ncbi.nlm.nih.gov
Background Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β 2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
[HTML][HTML] Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
C Vogelmeier, D Ramos-Barbon… - Respiratory …, 2010 - respiratory-research.biomedcentral …
Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist for the treatment of
chronic obstructive pulmonary disease (COPD). This randomized, double-blind study …
chronic obstructive pulmonary disease (COPD). This randomized, double-blind study …
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
C Vogelmeier, D Ramos-Barbon, D Jack… - Respiratory …, 2010 - search.proquest.com
Background: Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β 2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
C Vogelmeier, D Ramos-Barbon… - Respiratory …, 2010 - pubmed.ncbi.nlm.nih.gov
Background Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.
C Vogelmeier, D Ramos-Barbon, D Jack… - Respiratory …, 2010 - europepmc.org
Background Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist for the
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …
treatment of chronic obstructive pulmonary disease (COPD). This randomized, double-blind …